Platform

Innovative and Versatile Single Cell Platform

Our microfluidic system is a multifunctional platform enabling high-throughput single-cell analysis, including functional screening, sorting, and multi-omic immune cell profiling. Individual cells are encapsulated in picoliter droplets. Droplets act as independent reactors that are generated and analyzed at thousands of droplets per second.

Enhancing Success from Target to Patient
Our unique Drug Intelligence Science (DIS™) approach combines a cutting-edge single-cell platform with AI based data analysis to maximize the probability of success throughout the drug discovery and development process.

DIS™ powered data analysis and novel droplet-based target discovery allows us to harness the power of machine learning to obtain biologically relevant insights at the single-cell level.  AI and machine learning enable unprecedented cross-dataset analysis in the single-cell space and empower us to discover novel targets with strong translatability into curative therapies.

DIS™ powered antibody discovery allows for the screening of millions of species agnostic B cells within hours (CelliGo™) and analysis with proprietary single-cell bioinformatics (AbSolution™). Our machine learning model guides antibody binding prediction and affinity maturation.  

DIS™ powered single-cell profiling of patient samples together with AI and machine learning, we can identify indications where our therapeutics can achieve immune modulation and discover predictive biomarkers for patient treatment response, ultimately leading to an increase in the success rates of treatments.

Enhancing Success from Target to Patient
Our unique Drug Intelligence Science (DIS™) approach combines a cutting-edge single-cell platform with AI based data analysis to maximize the probability of success throughout the drug discovery and development process.

DIS™ powered data analysis and novel droplet-based target discovery allows us to harness the power of machine learning to obtain biologically relevant insights at the single-cell level.  AI and machine learning enable unprecedented cross-dataset analysis in the single-cell space and empower us to discover novel targets with strong translatability into curative therapies.

DIS™ powered antibody discovery allows for the screening of millions of species agnostic B cells within hours (CelliGo™) and analysis with proprietary single-cell bioinformatics (AbSolution™). Our machine learning model guides antibody binding prediction and affinity maturation.  

DIS™ powered single-cell profiling of patient samples together with AI and machine learning, we can identify indications where our therapeutics can achieve immune modulation and discover predictive biomarkers for patient treatment response, ultimately leading to an increase in the success rates of treatments.